A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- Registration Number
- NCT00937560
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This single arm study evaluated the efficacy and safety of first-line chemotherapy with carboplatin and dose-dense weekly paclitaxel plus bevacizumab (Avastin) in participants with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Participants received 6-8 3-week cycles of treatment with bevacizumab 7.5 mg/kg intravenously (iv) on Day 1 of each cycle, paclitaxel 80 mg/m\^2 iv on days 1, 8, and 15 of each cycle, and carboplatin iv to an area under the curve (AUC) of 6 on day 1 of each cycle. Following combination chemotherapy, bevacizumab could be continued to be given as a monotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 190
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Bevacizumab + paclitaxel + carboplatin Bevacizumab Participants received 6-8 (at the investigator's discretion) 3-week cycles of bevacizumab 7.5 mg/kg intravenously (iv) on Day 1 of each cycle, paclitaxel 80 mg/m\^2 iv on Days 1, 8, and 15 of each cycle, and carboplatin iv to an area under the curve of 6 on Day 1 of each cycle. The initial dose of carboplatin was calculated according to the Calvert formula (mg = \[glomerular filtration rate + 25\] x 6). Following the combination treatments, participants received up to 17 3-week cycles of bevacizumab 7.5 mg/g iv alone. Bevacizumab + paclitaxel + carboplatin Paclitaxel Participants received 6-8 (at the investigator's discretion) 3-week cycles of bevacizumab 7.5 mg/kg intravenously (iv) on Day 1 of each cycle, paclitaxel 80 mg/m\^2 iv on Days 1, 8, and 15 of each cycle, and carboplatin iv to an area under the curve of 6 on Day 1 of each cycle. The initial dose of carboplatin was calculated according to the Calvert formula (mg = \[glomerular filtration rate + 25\] x 6). Following the combination treatments, participants received up to 17 3-week cycles of bevacizumab 7.5 mg/g iv alone. Bevacizumab + paclitaxel + carboplatin Carboplatin Participants received 6-8 (at the investigator's discretion) 3-week cycles of bevacizumab 7.5 mg/kg intravenously (iv) on Day 1 of each cycle, paclitaxel 80 mg/m\^2 iv on Days 1, 8, and 15 of each cycle, and carboplatin iv to an area under the curve of 6 on Day 1 of each cycle. The initial dose of carboplatin was calculated according to the Calvert formula (mg = \[glomerular filtration rate + 25\] x 6). Following the combination treatments, participants received up to 17 3-week cycles of bevacizumab 7.5 mg/g iv alone.
- Primary Outcome Measures
Name Time Method Progression-free Survival Baseline to the data cut-off date of 19 Jul 2012 for analysis of the primary Outcome Measure (follow-up time up to 3 years, 1 month) Progression-free survival was defined as the time from the first administration of any study treatment to the first disease progression using Response Evaluation Criteria In Solid Tumors (RECIST) or death from any cause, whichever occurred first.
- Secondary Outcome Measures
Name Time Method Biological Progression-free Interval Baseline to the data cut-off date of 19 Jul 2012 for analysis of the primary Outcome Measure (follow-up time up to 3 years, 1 month) Biological progression-free interval is defined as the interval from the date of the first administration of any study treatment to the date of the first documented serial elevation of the ovarian cancer mucin CA-125. More precisely, this is defined as the first documented increase in CA-125 levels as follows: (1) CA-125 greater than or equal to 2 times the upper level of normal (ULN) on 2 occasions at least 1 week apart (for patients with CA-125 within normal range pre-treatment) or (2) CA-125 greater than or equal to 2 times the ULN on 2 occasions at least 1 week apart (for patients with elevated CA-125 pre-treatment and initial normalisation of CA-125 on-treatment) or (3) CA-125 greater than or equal to 2 times the nadir value, which is the lowest observed CA-125 value per patient on 2 occasions at least 1 week apart (for patients with elevated CA-125 pre-treatment which never normalised).
Percentage of Participants With an Objective Response Baseline to the data cut-off date of 19 Jul 2012 for analysis of the primary Outcome Measure (follow-up time up to 3 years, 1 month) An objective response was defined as either a complete response (CR) or a partial response (PR). Using the Response Evaluation Criteria in Solid Tumors (RECIST), a CR was defined as the disappearance of all target lesions and all non-target lesions, normalization of tumor marker level, and no new lesions and a PR was defined as the disappearance of all target lesions and persistence of ≥ 1 non-target lesions and/or the maintenance of tumor marker level above the normal limits, or, at least a 30% decrease in the sum of the longest diameter of target lesions, and no new lesions or unequivocal progression of existing non-target lesions. Only participants with measurable disease were included in the analysis according to RECIST only. Only participants with a Baseline ovarian cancer mucin CA-125 level ≥ 2 times the upper limit of normal who had a ≥ 50% reduction of CA-125 from Baseline were included in the analysis according to CA-125 level.
Duration of Response Baseline to the data cut-off date of 19 Jul 2012 for analysis of the primary Outcome Measure (follow-up time up to 3 years, 1 month) Duration of response was defined as the interval between the date of the first documented response by RECIST to the date of first disease progression or death, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of 1 or more new lesions or the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Only participants with measurable disease were included in the analysis according to RECIST only. Only participants with a Baseline ovarian cancer mucin CA-125 level ≥ 2 times the upper limit of normal who had a ≥ 50% reduction of CA-125 from Baseline were included in the analysis according to CA-125 level.
Overall Survival at 1 Year and 2 Years Baseline to Year 2 Reported are the percentage of participants that were alive at 1 year and 2 years after enrolling in the study.
Trial Locations
- Locations (54)
Mc Haaglanden, Locatie Antoniushove; Interne Geneeskunde
🇳🇱Leidschendam, Netherlands
Universita' Cattolica Del Sacro Cuore; Reparto Ginecologia Oncologica
🇮🇹Campobasso, Molise, Italy
Clinique Tivoli; Sce Radiotherapie
🇫🇷Bordeaux, France
Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie
🇫🇷Bordeaux, France
Medisch Spectrum Twente Enschede; Internal Medicine
🇳🇱Enschede, Netherlands
Chi Alpes Du Sud Site De Gap; Med Interne Et Polyvalente
🇫🇷GAP, France
Medical Radiological Scientific Center; Department of Radiotherapy of Gynaecological Disease
🇷🇺Obninsk, Kaluzhskaya Region, Russian Federation
City Clinical Oncology Hospital
🇷🇺Moscow, Russian Federation
Hospital Univ Vall d'Hebron; Servicio de Oncologia
🇪🇸Barcelona, Spain
Centre Hospitalier Henri Duffaut; Hematologie
🇫🇷Avignon, France
Hospital Universitario Clínico San Carlos; Servicio de Oncologia
🇪🇸Madrid, Spain
Centre Alexis Vautrin; Oncologie Medicale
🇫🇷Vandoeuvre Les Nancy, France
Hopital Antoine Beclere; Service de Medecine Interne
🇫🇷Clamart, France
Academisch Medisch Centrum; Inwendige Geneeskunde
🇳🇱Amsterdam, Netherlands
Sahlgrenska Universitetssjukhuset; Onkology
🇸🇪Gothenburg, Sweden
Instituto Valenciano Oncologia; Oncologia Medica
🇪🇸Valencia, Spain
Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital das Clinicas - FMUSP, Oncologia
🇧🇷Sao Paulo, SP, Brazil
Institut Claudius Regaud; Departement Oncologie Medicale
🇫🇷Toulouse, France
Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia
🇪🇸Barcelona, Spain
Akademiska sjukhuset, Onkologkliniken
🇸🇪Uppsala, Sweden
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
🇪🇸Valencia, Spain
Hospital Amaral Carvalho
🇧🇷Jau, SP, Brazil
Uni Hospital Linkoeping; Dept. of Oncology
🇸🇪Linköping, Sweden
Norrlands Uni Hospital; Onkologi Avd.
🇸🇪Umea, Sweden
Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
🇪🇸Malaga, Spain
Örebro University Hospital; Department of Gynecologic Oncology
🇸🇪Örebro, Sweden
Ch De Brive La Gaillarde; Radiotherapie Oncologie
🇫🇷Brive La Gaillarde, France
Centre Georges Francois Leclerc; Oncologie 3
🇫🇷Dijon, France
Institut Daniel Hollard
🇫🇷Grenoble, France
Hôpital Saint Joseph; Oncologie Medicale
🇫🇷Marseille, France
GH Paris Saint Joseph; Hopital De Jour Oncologie
🇫🇷Paris, France
Centro Oncologico MD Anderson Internacional; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Universitario La Paz; Servicio de Oncologia
🇪🇸Madrid, Spain
Hopital De La Miletrie; Hematologie Et Oncologie Medicale
🇫🇷Poitiers, France
HOPITAL TENON; Cancerologie Medicale
🇫🇷Paris, France
Centre Antoine Lacassagne; Hopital De Jour A2
🇫🇷Nice, France
CHRA;Hematologie
🇫🇷Metz Tessy, France
Institut de Cancerologie de La Loire; Radiotherapie
🇫🇷St Priest En Jarez, France
Centre Paul Strauss; Oncologie Medicale
🇫🇷Strasbourg, France
IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica B
🇮🇹Napoli, Campania, Italy
A.O. Universitaria Policlinico Di Modena; Oncologia
🇮🇹Modena, Emilia-Romagna, Italy
Medisch Centrum Alkmaar
🇳🇱Alkmaar, Netherlands
Sint Elizabeth Ziekenhuis; Inwendige Geneeskunde
🇳🇱Tilburg, Netherlands
Academ Ziekenhuis Groningen; Medical Oncology
🇳🇱Groningen, Netherlands
Isala Klinieken, Locatie Sophia; Inwendige Geneeskunde
🇳🇱Zwolle, Netherlands
The Norvegian Radium Hospital Montebello; Dept of Oncology
🇳🇴Oslo, Norway
Regional Clinical Oncology Dispensary
🇷🇺Krasnodar, Russian Federation
Oncology Hospital; Chemotherapy Dept.
🇷🇺Moscow, Russian Federation
Russian Oncology Research Center n.a. N.N. Blokhin Dpt of Clinical Pharmacology and Chemotherapy
🇷🇺Moscow, Russian Federation
SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary
🇷🇺Stavropol, Russian Federation
St. Petersburg Oncology & Gynecology; City Clinical Oncology Dispensary
🇷🇺Saint-Petersburg, Russian Federation
Royal Marsden Hospital; Dept of Med-Onc
🇬🇧London, United Kingdom
St. Olavs Hospital; Kvinneklinikken
🇳🇴Trondheim, Norway